Carfilzomib
2011-003
Phase 3 small_molecule completed
Quick answer
Carfilzomib for Multiple Myeloma is a Phase 3 program (small_molecule) at Amgen with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Multiple Myeloma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed